

# Practical Concepts in Hair Loss

**Curtis T. Thompson, M.D.**

CTA Pathology

Volunteer Adjunct Associate Professor of Dermatology

University of Miami Miller School of Medicine

and

Clinical Professor of Dermatology and Pathology

Oregon Health and Science University

# Lecture Objectives


- Practical biopsy technique/specimen submission
- Hair biology--correlate with hair loss processes
- LPP/FFA

# Keys to a Diagnostic Biopsy


- Important clinical information for pathology
  - Patchy or Diffuse
  - Shedding or +Hair pull test
  - Duration of loss
  - Exact location of biopsy
  - Age, sex, ethnicity/race/skin type

# Keys to a Diagnostic Biopsy

- Straight hair—parallel to fibers at exit of scalp.
- Curly hair—perpendicular to scalp.
- Advancing edge with +pull test



Perpendicular to scalp




Parallel to hairs

## Three-dimensional imaging of a peripilar cast and compound follicle in frontal fibrosing alopecia


Curtis T Thompson<sup>1 2</sup>, Maria Abril Martinez Velasco<sup>3</sup>, Antonella Tosti<sup>4</sup>




# *In vivo* confocal microscopy



# 2mm Transverse H&E sections








# A method for more precise sampling of the scalp and eyebrows in frontal fibrosing alopecia

Curtis T. Thompson, MD,<sup>a,b,c</sup> and Antonella Tosti, MD<sup>d</sup>  
*Portland, Oregon, and Miami, Florida*



3 slides total with 9 cross sections; 3 sections per slide

1. Tissue is embedded epidermis-down
2. Step through entire block on initial H&E stains
3. Obtain unstained slides

## Three-dimensional imaging of a peripilar cast and compound follicle in frontal fibrosing alopecia

Curtis T Thompson<sup>1 2</sup>, Maria Abril Martinez Velasco<sup>3</sup>, Antonella Tosti<sup>4</sup>






# Keys to a Diagnostic Biopsy

- Mark area identified with dermatoscope and then verify site again before biopsy
- 4mm punch—push deep
- Avoid biopsy of end-stage scarring—edges of patch
- Avoid areas with secondary changes.
- Multiple biopsies if ? > than one process possible.

# Keys to a Diagnostic Biopsy



- Cultures—Mince tissue (homogenate)
- Direct Immunofluorescence—as needed—  
LE vs LPP.
- Specials stains
  - Infectious.
  - Colloidal iron stain for primary perifollicular scarring.


# Vertical to Horizontal Sections




# Normal Follicular Size

- SIZE 4:1 Ratio (2:1 >40 y/o)
  - Terminal
    - Bulbs in subcutis
    - Thicker than 0.06mm
  - Vellus or Miniaturized
    - 1/2 diameter of terminal (0.03mm)
    - Inner root sheath as thick as hair shaft
    - Not pigmented










# Concept

- All alopecia is ultimately scarring.











# Follicular Anatomy

# Folliculo-Sebaceous-Apocrine Unit

- **Infundibulum**
- **Isthmus**
- **Suprabulbar zone**
- **Hair bulb**








# Hair Cycle Phases

# Normal Hair Cycle




# Normal Hair Cycle—Scalp

- Anagen: >85% of all hairs; 2-7years in length
- Catagen: <2%; 2 weeks
- Telogen: <15%; 5 weeks




# Phases of Growth

## Anagen





- Growth phase
- 90 % of hairs
- 3-7 years period

## Catagen



- Involution phase
- Less than 1% of hairs
- Last few weeks
- Apoptosis, thick BM
- Involution distal to isthmus

## Telogen




- Resting phase
- 10% hairs
- 2-6 months

# Duration of Anagen Phase=Hair Length

- Scalp 2-7 years
- Pubic/Axillary 3 months
- Eyebrows/eyelashes <1 month

# Catagen-Telogen Importance in diagnosis

Acute  
Telogen  
Effluvium




Telogen  
Effluvium\*

\* “Chronic Telogen Effluvium”  
No identifiable cause


# Acute Telogen Effluvium.

- Profound, synchronized cycle into catagen/telogen




# Acute Telogen Effluvium.

- Shedding occurs several months after insult (fever, anesthesia, stress, drug ingestion).



# Acute Telogen Effluvium. Right after insult





# Acute Telogen Effluvium. During shedding




# Acute Telogen Effluvium

Histology: Near 100% anagen




# Telogen Effluvium

- High, non-synchronized cycling (short anagen).




# Telogen Effluvium

Histology: High catagen/telogen (>15%)




# Summary of Telogen Effluvium

Acute  
Telogen  
Effluvium



Near 100%  
Anagen

Telogen  
Effluvium



>15%  
Catagen/telogen

# Telogen Effluvium

- Concept: Hair loss is global—including face, pubic hair, etc.

# Diffuse Hair Loss

- Concept: Many non-diffuse alopecic processes may be diffuse in presentation (LPP, alopecia areata).

# Pattern Hair Loss


- Concept:
  - Men—Androgenetic
  - Women
    - Androgenetic—young
    - Senescence—older (>60)


# Pattern Alopecia


- Concept: Pattern of loss can occur in either males or females
  - Hamilton's 'male pattern'
  - Ludwig's 'female pattern'
  - Global loss


# Pattern Hair Loss

- Concept:
  - Miniaturization is hallmarked of pattern hair loss
  - However, miniaturization present in other entities (alopecia areata)











# Alopecia Areata

- Dramatic catagen/telogen shift
- Peribulbar lymphocytes




# Subtle (subacute) alopecia areata

## Often diffuse




# Alopecia Areata, Subacute Phase

- Dramatic catagen/telogen shift
- Follicular miniaturization
- Interstitial (not peribulbar) lymphocytes




# Alopecia Areata, Subacute Phase





# Alopecia Areata Simulants

## FPHL with Telogen Effluvium





# CD3 subacute alopecia areata




Kolivras A and Thompson CT. Distinguishing diffuse alopecia areata from pattern hair loss using CD3+ T-cells. *JAAD*. 74:937-44, 2016.

# CD3 for subacute alopecia areata



# Alopecia Areata Simulants

- Psoriasis
- Lupus
- Syphilis
- Permanent chemotherapy-induced alopecia




# Trichotillomania (Trichotillois)

- Often superimposed on another alopecic process


# Trichotillomania Treatment à la Dr. Vera Price (UCSF)

- Children (Type 1)—Transient; reassurance; no intervention.
- Adolescence/Young Adult (Type 2)—Deep-seated behavior disorder; psychopharmacologics (OCD; stress/anxiety).
- Adulthood (Type 3)—Often psychotic; prognosis poor. Either no intervention or drugs.


# Trichotillomania: Catagen-Telogen




# Trichotillomania: LSC/excoriation




# Trichotillomania



# Trichotillomania—Broken hair shafts



# Trichotillomania—Broken hair shafts



# LPP vs Folliculitis decalvans

## Lymphocytic

Chronic cutaneous lupus erythematosus  
Lichen planopilaris

Classic lichen planopilaris  
Frontal fibrosing alopecia  
Graham-Little syndrome  
Classic pseudopelade (Brocq)  
Central centrifugal cicatricial alopecia  
Alopecia mucinosa  
Keratosis follicularis spinulosa decalvans

## Neutrophilic

Folliculitis decalvans  
Dissecting cellulitis/folliculitis (*perifolliculitis capitis  
abscedens et suffodiens*)

## Mixed

Folliculitis (acne) keloidalis  
Folliculitis (acne) necrotica  
Erosive pustular dermatosis

## Nonspecific

Summary of North American Hair Research Society (NAHRS)-  
sponsored Workshop on Cicatricial Alopecia, Duke University  
Medical Center, February 10 and 11, 2001

Elise A. Olsen, MDa • Wilma F. Bergfeld, MDb • George Cotsarelis, MDc • Vera H. Price, MDd •  
Jerry Shapiro, MDe • Rodney Sinclair, MDF • Alvin Solomon, MDg • Leonard Sperling, MDh • Kurt Stenn, MDi •  
David A. Whiting, MDj the members of the Workshop on Cicatricial Alopecia • Show less

DOI: <https://doi.org/10.1067/mjd.2003.68>



# Folliculitis decalvans vs LPP

- Folliculitis decalvans
  - Men under age 40
- Lichen Planopilaris
  - Women over age 40



# Folliculitis decalvans vs LPP

- Folliculitis decalvans
  - Men under age 40
- Lichen Planopilaris
  - Women over age 40
- CCCA
  - Women of African descent



# Folliculitis decalvans vs LPP



# Perifollicular vs Interstitial



# Tufted compound follicles






# Lichen Planopilaris (LPP)



Premature desquamation of the inner root sheath

=

Squamotization of follicular epithelium



# Perifollicular (concentric lamellar) mucinous fibroplasia




# Pseudopelade of Brocq





# Normal ostium vs Compound follicle



≠




# Lichen Planopilaris (LPP)




Loss of catagen/telogen phase follicles

# Near absence of catagen/telogen in LPP




# Cytokeratin 15



Habashi-Daniel et al. Absence of catagen/telogen phase and loss of cytokeratin 15 expression in hair follicles in lichen planopilaris. *JAAD* 71:969-72, 2014.

# Loss of Cytokeratin 15 in LPP




# Lichen Planopilaris Progression


Loss of CK15+  
stem cells



Disappearance of  
follicle when  
cycle into catagen



Clinical progression  
despite  
immunosuppressive  
treatment



# Lichen Planopilaris (LPP)

Absence of  
catagen/telogen

Loss of CK15+  
stem cells

**EARLY INTERVENTION IS LIKELY  
THE BIGGEST FACTOR IN  
PROGNOSIS.**

Habashi-Daniel A, Roberts J, Desai N, Thompson C. Absence of Catagen/Telogen Phase and Loss of Cytokeratin 15 Expression in Hair Follicles in Lichen Planopilaris (LPP). Submitted for publication, 2013.

## Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution.

*Kossard S*<sup>1</sup>.

⊕ **Author information**  Papers ▾

### Erratum in


*Arch Dermatol* 1994 Nov;130(11):1407.


### Abstract

**BACKGROUND:** Recession of the frontal hairline is a common event in postmenopausal women. This has been shown not to be a marker of gross androgenization, and is usually a progressive nonscarring alopecia. Six postmenopausal women, who developed a progressive frontal scarring alopecia, were studied and their clinical and laboratory data, as well as the results of scalp biopsy specimens in all six patients, were analyzed and compared with recognized forms of scarring alopecia and recently described findings in androgenetic alopecia.

**OBSERVATIONS:** The six postmenopausal women developed a progressive frontal hairline recession that was associated with perifollicular erythema within the marginal hairline, producing a frontal fibrosing alopecia extending to the temporal and parietal hair margins. Scalp biopsy specimens from the frontal hair margin showed perifollicular fibrosis and lymphocytic inflammation concentrated around the isthmus and infundibular areas of the follicles. Immunophenotyping of the lymphocytes showed a dominance of activated T-helper cells. Clinical review of all six cases showed a progressive marginal alopecia without the typical multifocal areas of involvement seen in lichen planopilaris or pseudopelade. None of the patients had mucous membrane or skin lesions typical of lichen planus. Hormonal studies, in five patients, showed no elevated androgen abnormalities.



**CONCLUSIONS:** Progressive frontal recession in postmenopausal women may show clinical features of a fibrosing alopecia. The histologic findings are indistinguishable from those seen in lichen planopilaris. However, the absence of associated lesions of lichen planus in all six women raises the possibility that this mode of follicular destruction represents a reaction pattern triggered by the events underlying postmenopausal frontal hairline recession.






100  $\mu$ m

# Subtle perifollicular (concentric lamellar) mucinous fibroplasia in FFA






100 μm

# Frontal Fibrosing Alopecia


## Minimal perifollicular scarring



# Frontal Fibrosing Alopecia

- Target smaller follicles of the skin
  - Frontal hairline
  - Eyebrows
  - Facial hair
  - Body hair

# FFA—Eyebrow Involvement





# Facial papules: FFA or rosacea?



# Demodex

## Cause of inflammation and pruritus



# Facial papules in FFA

Keratin plugging of infundibula and acrosyringia


Lichenoid infiltrate of vellus follicles

Perifollicular fibrosis


C

Lopez-Pestaña A *et al.* J Am Acad Dermatol 73:987.e1-6, 2015.


# Facial papules in FFA




# Facial papules in FFA



# Facial papules in FFA



# Facial papules in FFA



? Rosacea or FFA



# Facial Papules: FFA or rosacea?



# Facial papules in FFA

- Confusing reports to on exact histopathology
- Biopsy generally not needed unless FFA has not yet been diagnosed

# Frontal Fibrosing Alopecia--Limbs



## Frontal Fibrosing Alopecia Involving the Limbs Shows Inflammatory Pattern on Histology: A Review of 13 Cases

Miteva, Mariya MD [Author Information](#) ☺

The American Journal of Dermatopathology: March 2020 - Volume 42 - Issue 3 - p 226-229  
doi: 10.1097/DAD.0000000000001500




# Histologic absence of yeast as a clue for classic lichen planopilaris, fibrosing alopecia in a pattern distribution, and frontal fibrosing alopecia: A cross-sectional observational study

[Kimberly Williams, BS](#)<sup>a</sup> · [Antonella Tosti, MD](#)<sup>a</sup> · [Curtis T. Thompson, MD](#) <sup>b,c</sup> 


JAAD International, Volume 19, 10 - 11

There was a distinct difference between the absence and presence of yeast between cases of LPP/FAPD/FFA and FPHL. In LPP/FAPD/FFA, 98.5% (68/69) of cases had no identifiable yeast. In contrast, in FPHL 50% (34/68) of cases had identifiable yeast ( $P < .001$ ).


# Absence of yeast clue LPP/FFA



No sebaceous = No yeast




=



# Lupus Erythematosus



- Most lesions like discoid LE elsewhere
- SLE regrows





# Chronic cutaneous (discoid) lupus erythematosus presenting as FFA



# LE presenting as FFA



# Lupus $\neq$ LPP/FFA



[Arch Dermatol](#). 1994 Jun;130(6):770-4.

## Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution.

[Kossard S](#)<sup>1</sup>.

[+ Author information](#) [+ Papers](#) ▾

### Erratum in

[Arch Dermatol](#) 1994 Nov;130(11):1407.


# Fibrosing Alopecia in a Pattern Distribution FAPD

associated with perifollicular erythema within the marginal hairline, producing a frontal fibrosing alopecia extending to the temporal and parietal hair margins. Scalp biopsy specimens from the frontal hair margin showed perifollicular fibrosis and lymphocytic inflammation concentrated around the isthmus and infundibular areas of the follicles. Immunophenotyping of the lymphocytes showed a dominance of activated T-helper cells. Clinical review of all six cases showed a progressive marginal alopecia without the typical multifocal areas of involvement seen in lichen planopilaris or pseudopelade. None of the patients had mucous membrane or skin lesions typical of lichen planus. Hormonal studies, in five patients, showed no elevated androgen abnormalities.

**CONCLUSIONS:** Progressive frontal recession in postmenopausal women may show clinical features of a fibrosing alopecia. The histologic findings are indistinguishable from those seen in lichen planopilaris. However, the absence of associated lesions of lichen planus in all six women raises the possibility that this mode of follicular destruction represents a reaction pattern triggered by the events underlying postmenopausal frontal hairline recession.


# Is there a pathogenetic link between frontal fibrosing alopecia, androgenetic alopecia and fibrosing alopecia in a pattern distribution?

A C Katoulis <sup>1</sup>, K Diamanti <sup>1</sup>, D Sgouros <sup>1</sup>, A I Liakou <sup>1</sup>, E Bozi <sup>1</sup>, G Avgerinou <sup>2</sup>, I Panayiotides <sup>3</sup>,  
D Rigopoulos <sup>2</sup>



# Fibrosing alopecia in a pattern distribution (FAPD)

- FPHL
- LPP (diffuse)



# Lichen Planopilaris (LPP)

- Mini-Epidemic?
  - Hair loss clinicians observing increased incidence.
  - Traditionally West Coast > East Coast

# Lichen Planopilaris

## Increasing Incidence

- ?Nanoparticle?
  - Sunscreen?
  - Lichen planus—Metals, especially dental implicated
    - Gold, mercury—dental\*
    - Nail LP associated with +metal patch test\*\*

\*Sasaki G et al. J Dermatol 23:890, 1996.

\*\*Nishizawa A et al. J Eur Acad Dermatol Venerol 27:e231, 2013.

## Frontal fibrosing alopecia: possible association with leave-on facial skin care products and sunscreens; a questionnaire study.

Aldoori N<sup>1</sup>, Dobson K<sup>1</sup>, Holden CR<sup>1</sup>, McDonagh AJ<sup>1</sup>, Harries M<sup>2</sup>, Messenger AG<sup>3</sup>.

### ⊕ Author information

#### Abstract

**BACKGROUND:** Since its first description in 1994, frontal fibrosing alopecia (FFA) has become increasingly common, suggesting that environmental factors are involved in the aetiology.

**OBJECTIVES:** To identify possible causative environmental factors in FFA.

**METHODS:** A questionnaire enquiring about exposure to a wide range of lifestyle, social and medical factors was completed by 105 women with FFA and 100 age- and sex-matched control subjects. A subcohort of women with FFA was patch tested to an extended British standard series of allergens.

**RESULTS:** The use of sunscreens was significantly greater in the FFA group compared with controls. Subjects with FFA also showed a trend towards more frequent use of facial moisturizers and foundations but, compared with controls, the difference in frequencies just failed to reach statistical significance. The frequency of hair shampooing, oral contraceptive use, hair colouring and facial hair removal were significantly lower in the FFA group than in controls. Thyroid disease was more common in subjects with FFA than controls and there was a high frequency of positive patch tests in women with FFA, mainly to fragrances.

**CONCLUSIONS:** Our findings suggest an association between FFA and the use of facial skin care products. The high frequency of sunscreen use in patients with FFA, and the fact that many facial skin care products now contain sunscreens, raises the possibility of a causative role for sunscreen chemicals. The high frequency of positive patch tests in women with FFA and the association with thyroid disease may indicate a predisposition to immune-mediated disease.

**Frontal fibrosing alopecia in men: an association with facial moisturizers and sunscreens**

DOI: 10.1111/bjd.15311

DEAR EDITOR, Frontal fibrosing alopecia (FFA) was first described by Kossard in 1994 in six postmenopausal women.<sup>1</sup> FFA remained rare during the 1990s, but in the last 10–15 years it has become increasingly common, a phenomenon observed worldwide. The recent onset and apparently rising incidence of FFA suggest involvement of environmental factors in the aetiology. We previously reported a questionnaire study in women with FFA that asked about a wide range of medical, social and environmental exposures. The results suggested an association between FFA and leave-on facial products, including moisturizers and sunscreens.<sup>2</sup> However, although the regular use of moisturizers was greater in women with FFA, these products are used by most women and we were unable to show a significant difference in their use between women with FFA and similarly aged controls. The use of primary sunscreens was significantly greater among women with FFA than in controls, but we were not able to assess whether patients were also exposed to sunscreens from other sources.

We have therefore repeated our questionnaire study in men with FFA, as we anticipated that their use of leave-on facial skincare products would be lower than in women.

As FFA is rare in men, patients were recruited from across the U.K. and one case was recruited from Belgium. In all cases the diagnosis was made by a clinician with special expertise in hair disease, and it was supported by histology in most cases. The clinical diagnosis was based on scarring alopecia affecting the frontal hairline causing recession of the hairline. Additional features included loss of eyebrows, follicular erythema of the frontal hairline and loss of sideburn and beard hair. Male controls aged 35–80 years were recruited from three sites (Sheffield, Salford and Glasgow). The patients completed a questionnaire similar to that used in our female study, but inviting more detailed information on the use of facial skincare and hair care products. Male patients with FFA were asked about the timing and distribution of hair loss, but otherwise the questionnaires completed by both groups were identical.

Seventeen men with FFA and 73 controls were recruited. The mean age of onset of hair loss in the patients with FFA was 54.5 years (range 35–77). All had loss of hair from the frontal hairline, and 16 (94%) had lost eyebrows. Twelve

men (71%) reported loss of hair from the beard and 13 (76%) reported loss of hair from the limbs. All men with FFA reported using facial moisturizers, compared with 40% in the control group. Facial moisturizers were used at least twice a week by 94% of patients with FFA, but by only 32% of controls ( $P < 0.001$ ) (Table 1). Sixteen patients reported using moisturizers for a period consistent with their use prior to the onset of FFA. The use of primary sunscreens by men with FFA was significantly more common than by controls. Overall 35% of men with FFA reported using a sunscreen at least twice a week all year round, compared with 4% of controls ( $P = 0.0012$ ).

When moisturizers containing sunscreen chemicals were included in the analysis, at least 71% of men with FFA applied a product containing a sunscreen at least twice a week all year

**Table 1** Reported use of skincare and hair care products by patients with frontal fibrosing alopecia (FFA) and controls

	Patients with FFA	Controls	P-value
Number of patients	17	73	
Age (years), mean (range)	63.1 (42–80)	59.1 (37–79)	
Age at onset of hair loss (years), mean (range)	54.5 (35–77)		
Facial moisturizer <sup>a</sup>	16 (94)	23 (32)	< 0.001
Primary sunscreen <sup>b</sup>	6 (35)	3 (4)	0.0012
Sunscreen <sup>b</sup>	12 (71)	8 (11)	< 0.001
Facial cleanser <sup>a</sup>	4 (24)	5 (7)	0.066
Facial scrub <sup>a</sup>	0	0	
Facial mask <sup>a</sup>	0	0	
Aftershave <sup>c</sup>	7 (41)	28 (39)	1.00
Shampoo <sup>a</sup>	13 (76)	62 (85)	0.27
Conditioner <sup>a</sup>	4 (24)	13 (18)	0.73
Hair spray <sup>a</sup>	1 (6)	2 (3)	0.48
Hair mousse <sup>a</sup>	0	0	
Hair gel <sup>a</sup>	2 (12)	10 (14)	1.00
Hair dye <sup>c</sup>	2 (12)	3 (4)	0.26

Values are n (%) unless stated otherwise. <sup>a</sup>Twice a week or more frequently. <sup>b</sup>Twice a week or more frequently all year round. <sup>c</sup>At least once a year. Sunscreen includes exposure to sunscreen chemicals in primary sunscreens and moisturizers. Analyses were performed after excluding subjects who failed to answer the question. Frequencies in the FFA and control groups were compared using Fisher's exact test.

**Table 1** Reported use of skincare and hair care products by patients with frontal fibrosing alopecia (FFA) and controls

	Patients with FFA	Controls	P-value
Number of patients	17	73	
Age (years), mean (range)	63.1 (42–80)	59.1 (37–79)	
Age at onset of hair loss (years), mean (range)	54.5 (35–77)		
Facial moisturizer <sup>a</sup>	16 (94)	23 (32)	< 0.001
Primary sunscreen <sup>b</sup>	6 (35)	3 (4)	0.0012
Sunscreen <sup>b</sup>	12 (71)	8 (11)	< 0.001
Facial cleanser <sup>a</sup>	4 (24)	5 (7)	0.066
Facial scrub <sup>a</sup>	0	0	
Facial mask <sup>a</sup>	0	0	
Aftershave <sup>a</sup>	7 (41)	28 (39)	1.00
Shampoo <sup>a</sup>	13 (76)	62 (85)	0.27
Conditioner <sup>a</sup>	4 (24)	13 (18)	0.73
Hair spray <sup>a</sup>	1 (6)	2 (3)	0.48
Hair mousse <sup>a</sup>	0	0	
Hair gel <sup>a</sup>	2 (12)	10 (14)	1.00
Hair dye <sup>c</sup>	2 (12)	3 (4)	0.26

Values are n (%) unless stated otherwise. <sup>a</sup>Twice a week or more frequently. <sup>b</sup>Twice a week or more frequently all year round. <sup>c</sup>At least once a year. Sunscreen includes exposure to sunscreen





Fig. 1 Right: a backscattered electron image taken from one of typical hair shafts with SEM showing the presence of particles with brighter contrast on a hair shaft; Left: EDX spectra collected from particle 1-3 showing the presence of Ti species on particle 1 and 3.

# Sunscreen

- Avobenzene, Homosalate, Octinoxate, Octisalate, Octocrylene, **Oxybenzone**
- Sd Alcohol 40, C12-15 Alkyl Benzoate, Acrylates Octylacrylamide Copolymer, Caprylyl Glycol, Dimethyl Capramide, Aloe Barbadensis (**Aloe Vera**) Leaf Extract, Retinyl Palmitate, Tocopherol, Fragrance.

Sun



Mirmirani, P., & Vanderweil, S. G. (2020). Frontal fibrosing alopecia with involvement of the central hair part: distribution of hair loss corresponding to areas of sunscreen application. *Dermatology Online Journal*, 26(11).

# Fibrosing Alopecia in a Pattern Distribution

## Hair root touch-up dye?



### **5A/MEDIUM ASH BROWN**

WATER, C12-15 PARETH-3, AMMONIUM HYDROXIDE, OLETH-10, DILINOLEIC ACID, COCAMIDE MEA, LINOLEAMIDOPROPYL DIMETHYLAMINE DIMER DILINOLEATE, STEARETH-21, BEHENTRIMONIUM CHLORIDE, POLYQUATERNIUM-22, SODIUM SULFATE, FRAGRANCE, RESORCINOL, ERYTHORBIC ACID, p-PHENYLENEDIAMINE, CAMEL, p-AMINOPHENOL, m-AMINOPHENOL, IRON OXIDES, MICA, SODIUM SULFITE, N,N-BIS(2-HYDROXYETHYL)-p-PHENYLENEDIAMINE SULFATE, 1-NAPHTHOL, SODIUM METASILICATE, EDTA, SARGASSUM FILIPENDULA EXTRACT, HYPNEA MUSCIFORMIS EXTRACT, GELLIDIOLA ACEROSA EXTRACT, TITANIUM DIOXIDE.

# African people with FFA



# FFA Causation

Meta-Analysis

> Arch Dermatol Res. 2023 Oct;315(8):2313-2331.

doi: 10.1007/s00403-023-02604-7. Epub 2023 Apr 4.

## Frontal fibrosing alopecia and personal care product use: a systematic review and meta-analysis

Olivia Kam<sup>1</sup>, Sean Na<sup>2</sup>, William Guo<sup>3</sup>, Christina I Tejada<sup>3</sup>, Tara Kaufmann<sup>3</sup>

**Nine studies**  
**1,248 FFA patients**  
**1,459 controls.**

# FFA Causation (9 studies)

- Sunscreen OR 3.02
  - 4.61 (men)
  - 2.74 (women)
- Facial moisturizer
  - 5.07 (men)
  - 1.58 (women)

Kam O, Na S, Guo W, Tejada CI, Kaufmann T. Frontal fibrosing alopecia and personal care product use: a systematic review and meta-analysis. *Arch Dermatol Res.* 2023 Oct;315(8):2313-2331.

# No FFA association (9 studies)

- Facial cleanser, toner, aftershave
- Foundation
- Shampoo, conditioner, mousse, gel, dye, straightening/rebonding, perming

Kam O, Na S, Guo W, Tejada CI, Kaufmann T. Frontal fibrosing alopecia and personal care product use: a systematic review and meta-analysis. Arch Dermatol Res. 2023 Oct;315(8):2313-2331.

doi: 10.1001/jamadermatol.2024.6434.

# Epistasis of ERAP1 With 4 Major Histocompatibility Complex Class I Alleles in Frontal Fibrosing Alopecia: A Genome-Wide Association Study Meta-Analysis

- 6668 included patients
  - 1585 FFA (European female)
  - 5083 controls.

# FFA Genomic Associations

- Genome-wide significant associations at 4 genomic loci
  - HLA-A\*11:01, HLA-A\*33:01, HLA-B\*07:02, and HLA-B\*35:01.
  - ERAP1 gene mutation at 5q15

Rayinda T, Dand N, McSweeney SM, Christou E, Ung CY, Stefanato CM, Fenton DA, Harries M, Palamaras I, Tidman A, Holmes S, Koutalopoulou A, Ardern-Jones M, Kaur M, Papanikou S, Chasapi V, Vañó-Galvan S, Saceda-Corralo D, Melián-Olivera A, Azcarraga-Llobet C, Lobato-Berezo A, Bustamante M, Sunyer J, Starace MVR, Piraccini BM, Wiss IP, Senna MM, Singh R, Hillmann K, Kanti-Schmidt V, Blume-Peytavi U, McGrath JA, Simpson MA, Tziotzios C. Epistasis of ERAP1 With 4 Major Histocompatibility Complex Class I Alleles in Frontal Fibrosing Alopecia: A Genome-Wide Association Study Meta-Analysis. *JAMA Dermatol.* 2025 Mar 1;161(3):310-314.

# FFA Causation (Summary)


- Sunscreen (men and women) and Facial moisturizer (men)
- Genetic predisposition
  - (40% with association with 4 genomic loci)
    - HLA-A\*11:01, HLA-A\*33:01, HLA-B\*07:02, and HLA-B\*35:01.
    - ERAP1 gene mutation at 5q15

# Hypothesis:

## All caused by same chemical?

- Lichen planopilaris
- Frontal fibrosing alopecia
- Fibrosing alopecia in a pattern distribution
- Central centrifugal cicatricial alopecia
- Lichen planus pigmentosus

# Shared dysregulated pathways in cholesterol biosynthesis and ...



Eddy H C Wang, Isha Monga, Brigitte N Sallee, James C Chen, Alexa R Abdelaziz, Rolando Perez-Lorenzo, Lindsey A Bordone, Angela M Christiano, Primary cicatricial alopecias are characterized by dysregulation of shared gene expression pathways, *PNAS Nexus*, Volume 1, Issue 3, July 2022, pgac111.

# Hypothesis

- Does sun protection allow chronic inflammation to occur?
- If so, then different sunscreen products could promote LPP and FFA, especially in genetically-susceptible people.

## Frontal fibrosing alopecia: Regrowth following cessation of sunscreen on the forehead.

Cranwell WC<sup>1,2,3,4</sup>, Sinclair R<sup>1,5,6</sup>.



36 months after cessation

# Titanium Free Products



# Thank you very much!

- University of Miami
  - Antonella Tosti, Betty Nguyen and Kimberly Williams
- California
  - Paradi Mirmirani and Vera Price
- Belgium
  - Athanassios Kolivras
- Israel
  - Anna Lyakhovitsky
- Cicatricial Classification Working Group
  - Elise Olsen, Wilma Bergfeld, Dirk Elston, Lynne Goldberg, Eleanor Knopp, Mariya Miteva, John Seykora, Michelle Schneider, Len Sperling

curtis@ctapathology.com

Mahalo!

¡Gracias!

Merci beaucoup!

